^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Excerpt:
...Disease-free survival in the remaining 5 patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status`Compare overall survival (OS) for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status`Compare Lung cancer specific survival for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status`Evaluate the nature, severity and frequency of adverse effects and tolerability of MEDI4736`Evaluate the Quality of life in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status`Determine survival benefits participants judge necessary to make adjuvant immunotherapy worthwhile`Determine the incremental cost effectiveness and cost utility ratios for MEDI4736`Evaluate the predictive/prognostic significance of PD-L1 expression`Evaluation of changes in plasma/serum cytokines and other blood and tissue based biomarkers after treatment with MEDI4736 and at disease event`Explore polymorphisms that may be associated with outcomes...
Trial ID:
Source:
Title:
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Excerpt:
...EGFR mutant NSCLC with PD-L1 expression of 1% or higher is allowed if...
Trial ID:
Less C2 evidence
Source:
Title:
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
Published date:
06/30/2020
Excerpt:
Similarly, the 12-month OS rate was higher in patients with EGFR+ NSCLC versus those with ALK+ NSCLC (Supplementary Fig. 2).
DOI:
10.1016/j.lungcan.2020.06.032
Trial ID:
